Position in VKTX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,444,384
+$200,771 QoQ
Shares Held
37,026
-3.1% QoQ
Ownership
0.032%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#140
of 434 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in VKTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Waverly Advisors, LLC holds $25,407,818 across 23 Biotechnology names. VKTX ranks #4 (5.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
23,131 | $11,489,861 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,584 | $3,481,847 | |
| 3 | SYRE |
Spyre Therapeutics, Inc.
|
25,512 | $2,264,955 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
This page
|
37,026 | $1,444,384 | |
| 5 | EYPT |
EyePoint, Inc.
|
77,914 | $1,114,170 | |
| 6 | CRSP |
CRISPR Therapeutics AG
|
18,163 | $990,610 | |
| 7 | INCY |
Incyte Corp
|
8,628 | $978,070 | |
| 8 | EXEL |
Exelixis, Inc.
|
13,174 | $716,797 |
All Filings in VKTX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,444,384 | 37,026 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,243,613 | 38,218 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,333,884 | 37,916 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $1,118,976 | 42,579 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $1,084,009 | 40,906 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $1,013,913 | 41,984 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $1,946,368 | 48,369 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $2,275,551 | 35,943 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $2,520,943 | 47,556 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||